Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Instagram
  • Listen to CMAJ podcasts
Holiday Reading

The Mayan Doomsday’s effect on survival outcomes in clinical trials

Paul Wheatley-Price, Brian Hutton and Mark Clemons
CMAJ December 11, 2012 184 (18) 2021-2022; DOI: https://doi.org/10.1503/cmaj.121616
Paul Wheatley-Price
Paul Wheatley-Price and Mark Clemons are from the Department of Medicine, Division of Medical Oncology. Brian Hutton is with the Ottawa Health Research Institute Methods Centre, University of Ottawa, Ottawa, Ont.
MBChB MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: [email protected]
Brian Hutton
Paul Wheatley-Price and Mark Clemons are from the Department of Medicine, Division of Medical Oncology. Brian Hutton is with the Ottawa Health Research Institute Methods Centre, University of Ottawa, Ottawa, Ont.
MSc PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark Clemons
Paul Wheatley-Price and Mark Clemons are from the Department of Medicine, Division of Medical Oncology. Brian Hutton is with the Ottawa Health Research Institute Methods Centre, University of Ottawa, Ottawa, Ont.
MBBS MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Responses
  • Metrics
  • PDF
Loading

There is a great deal of speculation concerning the end of the world in December 2012, coinciding with the end of the Mesoamerican Long Count calendar (the “Maya calendar”). Such an event would undoubtedly affect population survival and, thus, survival outcomes in clinical trials. Here, we discuss how the outcomes of clinical trials may be affected by the extinction of all mankind and recommend appropriate changes to their conduct. In addition, we use computer modelling to show the effect of the apocalypse on a sample clinical trial.

Mostly true background

With the imminent completion of the Maya calendar, many “experts” suspect the end of the world will occur on Dec. 21, 2012.1,2 This impending apocalypse highlights the need to rapidly resolve many major issues in research methods. Being based in an academic institution and fully respectful and compliant with all issues concerning Good Clinical Practice guidelines, we have been told that a tenet of human research is that all clinical trials must report and disseminate statistical results in a timely manner for the benefit of patients and the wider scientific community.3 Given the anticipated effect of the apocalypse, hence known as Mayan Doomsday (MaD), on survival outcome measures, research methods must be adjusted for the expedited analysis of all clinical research currently in progress. We recognize that reviewers, editors and even readers of this article may find the premise of our commentary rather fantastical. However, we defend the importance of our opinion by quoting the great medical forefather Louis Pasteur:

Where observation is concerned, fortune favours only the prepared mind.

Stuff we did

Using computer modelling (described elsewhere ad nauseum, ad infinitum), we have generated Kaplan–Meier curves for the overall population to compare normal life expectancy from standard actuary tables (control group) with population survival after MaD (obliteration group). These methods were then hypothetically applied to a standard clinical trial design.

Figure
Image courtesy of © 2012 Thinkstock

Stuff we found out

The difference in survival between the control and obliteration groups is shown in Figure 1. For the control group, death occurs at a predictable and fairly uniform rate. However, MaD leads to a statistically significant, and clinically relevant, difference in survival between the control and obliteration groups (we’re pretty sure that, were it calculated, p would definitely be something really significant, and certainly less than 0.05). Oddly, despite censoring for major known sources of bias (e.g., astronauts currently aboard the international space station, as well as zombies, the undead, the Grateful Dead, Dungeons and Dragons players, men who have read Fifty Shades of Grey and other similar beings likely to be unaffected by the apocalypse), the obliteration group does not fall to 0. We have dubbed this slow rise in the obliteration curve the “zombie repopulation.”

Figure 1:
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1:

Survival curves for the overall population with and without the occurrence of Mayan doomsday. MaD = Mayan doomsday. Note heretofore unforeseen postapocalyptic zombie repopulation.

Additional modelling was done to assess the effects of MaD on a sample clinical trial comparing the efficacy of 2 fictional, although completely plausible, drugs: Toxico and Horribilum. As can be seen in Figure 2A, compared with patients receiving Horribilum, those receiving Toxico had longer median overall survival. When the effect of MaD is added to the model (Figure 2B), no difference in survival can be seen between the 2 drugs. Furthermore, any adverse events would not be able to be recorded owing to “the mother of all adverse events,” and any statistical significance between study arms would be lost.

Figure 2:
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2:

Kaplan–Meier curves comparing overall survival among patients receiving Toxico or Horribilum. (A) Results without the impact of Mayan doomsay. (B) Results with the impact of Mayan doomsday.

Chit chat

If we have been thinking clearly, then it is apparent that the end of the world will have catastrophic effects on statistical analyses of survival outcomes. We therefore recommend that all clinical trials should stop immediately, as MaD will negate all potential trial results.

However, are trials such as those between our two fictional drugs entirely redundant in the event of MaD? It is possible that some useful scientific data could be salvaged. Late effects of these drugs could potentially be studied during the zombie repopulation, assuming that the original consent forms would still be considered valid (surely folks on the ethics board will have survived). Unfortunately, this work may be pragmatically challenging, as we suspect that most members of research teams may themselves be obliterated. (Due to sheer misfortune, all of the authors of this paper missed the biannual “Defense Against Zombies” seminar held in our institution.)

The possibility of a zombie repopulation is an unexpected finding in the event of MaD. Before MaD, the walking dead were most commonly relegated to young adult novels and cable specialty channels and were not observable with standard scientific techniques. Their putative existence does, however, bring a new dimension to the recent opening of multiple survivorship centres — although, if the new world population is predominantly immortal, we have concerns for the capacity of such programs. However, we would never allow such practical considerations to impair the scientific process.

Conclusion

MaD is bad.

References

  1. ↵
    2012 phenomenon. Wikipedia. Available: http://en.wikipedia.org/wiki/2012_phenomenon (accessed 2012 Sept. 18).
  2. ↵
    1. MacDonald GJ
    . Does Maya calendar predict 2012 apocalypse? McLean (VA): USA Today; 2007. Available: http://usatoday30.usatoday.com/tech/science/2007-03-27-maya-2012_n.htm (accessed 2012 Sept. 18).
  3. ↵
    1. Vijayananthan A,
    2. Nawawi O
    . The importance of good clinical practice guidelines and its role in clinical trials. Biomed Imaging Interv J 2008;4:e5.
    OpenUrlPubMed
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 184 (18)
CMAJ
Vol. 184, Issue 18
11 Dec 2012
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The Mayan Doomsday’s effect on survival outcomes in clinical trials
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
The Mayan Doomsday’s effect on survival outcomes in clinical trials
Paul Wheatley-Price, Brian Hutton, Mark Clemons
CMAJ Dec 2012, 184 (18) 2021-2022; DOI: 10.1503/cmaj.121616

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
The Mayan Doomsday’s effect on survival outcomes in clinical trials
Paul Wheatley-Price, Brian Hutton, Mark Clemons
CMAJ Dec 2012, 184 (18) 2021-2022; DOI: 10.1503/cmaj.121616
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Mostly true background
    • Stuff we did
    • Stuff we found out
    • Chit chat
    • Conclusion
    • References
  • Figures & Tables
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Pareidolia and clinical reasoning: the pattern awakens
  • On the road from Bethany
  • LimitationsAn experiment in open peer review
Show more Holiday Reading

Similar Articles

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: [email protected]

CMA Civility, Accessibility, Privacy

 

Powered by HighWire